Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 8/20 | 0.61 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 10/20 | 0.51 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123178 | 1.00 | PDE10A (0.61) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL15043350 | 0.86 | PDE10A (0.61) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL15735061 | 0.84 | PDE10A (0.64) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL30123648 | 0.84 | PDE10A (0.64) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL15733493 | 0.80 | PDE10A (0.68) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL15043339 | 0.80 | PDE10A (0.78) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL15733023 | 0.80 | PDE10A (0.61) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL30123641 | 0.80 | PDE10A (0.78) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL15745979 | 0.79 | PDE10A (0.66) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 | |
| SCHEMBL15733219 | 0.79 | CSNK1D (0.65) | PDE10ACSNK1DCSNK1EMAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-02-01 | — | — | US | claimed |
| EP-2922842-B1 | INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC (US) | 2017-06-14 | — | — | EP | claimed |
| CN-104995183-A | Novel phosphodiesterase type 10A inhibitor compounds | ABBVIE INC | 2015-10-21 | — | — | CN | claimed |
| EP-2922842-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Inc. (US) | 2015-09-30 | — | — | EP | claimed |
| WO-2014079995-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2014-05-30 | — | — | WO | claimed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | claimed |
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| CN-104995183-B | Novel phosphodiesterase type 10A inhibitor compounds | 艾伯维公司 | 2018-04-06 | — | — | CN | disclosed |
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-02-01 | — | — | US | disclosed |
| US-9790203-B2 | Inhibitor compounds of phosphodiesterase type 10A | ABBVIE INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2922842-B1 | INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC (US) | 2017-06-14 | — | — | EP | disclosed |
| CN-104995183-A | Novel phosphodiesterase type 10A inhibitor compounds | ABBVIE INC | 2015-10-21 | — | — | CN | disclosed |
| EP-2922842-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Inc. (US) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079995-A2 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030033-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | PDE10A 17/4885CSNK1D 1340/4885CSNK1E 1575/4885 |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | PDE2A, PDE3A, PDE3B | PDE10A 5/4885CSNK1D 1175/4885CSNK1E 615/4885 |
| US-20140148461-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE1A, PDE1B, PDE3A | PDE10A 17/4885CSNK1D 1326/4885CSNK1E 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.